

SCALABLE CONTINUOUS FLOW ULTRACENTRIFUGATION

It is estimated **84% of the worldwide flu production** relies on units designed, built, and serviced by Alfa Wassermann Separation Technologies (AWST).


For **over 60 years**, AWST's continuous flow zonal ultracentrifuge has been a vital component in global production of the annual influenza vaccine.


These systems reliably operate year round yielding a product that results in **hundreds of millions of doses of vaccine**.

One of the great challenges to producing a SARS-CoV-2 vaccine is the need to produce hundreds of millions of doses. AWST ultracentrifuges address that challenge.



AWST KII Ultracentrifuge





SARS-CoV-2 Diameter = ~120 nm Density = 1.18 g/mL


Viral v Influenza suspe

Diameter = ~100 nm Density = 1.19 g/mL Both SARS-CoV-2, a coronavirus, and influenza are pleomorphic RNA viruses with similar sizes, shapes, densities, and surface proteins.

Viral vaccines generally require forming a suspension. **Ultracentrifugation is the standard** for purifying and concentrating suspensions.

Our unique ultracentrifugation technology bridges the gap between batch operation and large scale production featuring patented continuous flow operation. Scalability from vaccine development to large scale production is the hallmark of AWST's technology.

Scalability is rooted in our rotor design used in all AWST systems. During rotation, loaded sample particles separate radially utilizing the relatively simple physical phenomena of sedimentation, and once at rest they can be collected in fractions.





SCALABLE CONTINUOUS FLOW ULTRACENTRIFUGATION

Production Scale Manafacturing





Pilot Scale



Promatix	1000

pKII

KII

			••••
Rotor Size	230 mL	400, 800, or 1600 mL	3200, or 8000 mL
Typical Flow	0.25 – 2 L/h	Up to 15 L/h	Up to 60 L/h
Max. Speed	35,000 rpm	40,500 rpm	40,500 rpm
G Forces	90,500	121,200	121,200

Mobile Phase Stationary Gradient Phase Multiple cores are available with dimensional equivalent forces, only the process volume changes.


Constant k-factors

$$k = \frac{2.53 \times 10^{11} \ln(\frac{r_{max}}{r_{min}})}{r_{pm^2}}$$

r_{min} = 55 mm

 $r_{max} = 65 \text{ mm}$

Gradient formation and recovery is linearly scalable for a variety of materials (Sucrose, CsCl, and Iodixanol)





SCALABLE CONTINUOUS FLOW ULTRACENTRIFUGATION

Why choose Alfa Wassermann for your vaccine development?



Additionally, product recovery and process time can be improved with the AWST Automatic Fluid Handler that works in unison with the zonal ultracentrifuge.





Automated Fluid Handling System

Contact your AWST representative today at AWST.com